Endocrinologist Medical Fellow, Eli Lilly and Company, US
Dr. Krege completed his M.D. with Honors and Distinction and was a member of Alpha Omega Alpha Honor Society. He then took an internal medicine residency and an endocrinology fellowship at the University of North Carolina at Chapel Hill.
He was a Howard Hughes Medical Institute Postdoctoral Physician Fellow in the laboratory of Oliver Smithies (2007 Nobel Laureate) and then received a National Institutes of Health Clinical Investigator Development Award. His research focused on the genetics of the renin-angiotensin system and the estrogen receptors. He received a Merck Young Investigators Award for “Excellence in High Blood Pressure Research” and the Marion Merrell Dow “Hypertension Research Clinical Fellowship Program” for best hypertension research by a young physician. He is a Fellow of the American Heart Association.
After leaving Chapel Hill, he practiced endocrinology, was an investigator on numerous clinical trials, continued basic science work on the estrogen receptors as an Adjunct Assistant Professor at UNC-Chapel Hill, and taught students and residents from UNC-Chapel Hill and Wake Forest Medical Center. He was also Medical Director for a diabetes treatment center.
In 2002, Dr. Krege joined Lilly and was part of the team that achieved approval of Forteo. He has also worked extensively on Evista, arzoxifene, and blosozumab, and has helped design and provided medical leadership on many Lilly clinical trials of osteoporosis drugs. In 2006, he received the Lilly Research Laboratories President’s Recognition Award for Outstanding Scientific Achievements.